CBS 2019
CBSMD教育中心
中 文

充血性心力衰竭

Abstract

Recommended Article

Lower Risk of Heart Failure and Death in Patients Initiated on SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study HFpEF: From Mechanisms to Therapies Progression of Device-Detected Subclinical Atrial Fibrillation and the Risk of Heart Failure Improving the Use of Primary Prevention Implantable Cardioverter-Defibrillators Therapy With Validated Patient-Centric Risk Estimates Good response to tolvaptan shortens hospitalization in patients with congestive heart failure Cardiac Implantable Electronic Devices in Patients With Left Ventricular Assist Systems Can We Use the Intrinsic Left Ventricular Delay (QLV) to Optimize the Pacing Configuration for Cardiac Resynchronization Therapy With a Quadripolar Left Ventricular Lead? Respiratory Syncytial Virus and Associations With Cardiovascular Disease in Adults
|<< 1 2 3 4 5 6 7 ...>>|

JOURNAL： Article Link

经皮冠状动脉介入治疗后的积极降脂治疗--目标人群以及如何开展？

作者：Zhen-Vin Lee等 译者：左广峰 审校：姜潇

摘要

尽管经皮冠状动脉介入治疗 (PCI) 对阻塞性冠状动脉疾病的疗效是确切的，但考虑到非手术相关的其他重要危险因素的控制程度，尚不能确保长期预后。动脉粥样硬化作为血脂异常的结果，其发展导致的风险具有连续性，因此对接受PCI的患者采取二级预防措施，对于降低手术失败以及心血管事件的风险尤为重要。本综述通过总结最新临床指南推荐，强调三种主流降脂疗法相关理论和证据（即他汀类药物、依折麦布和前蛋白转化酶枯草杆菌蛋白酶/ kexin 9型（PCSK9）抑制剂），概述以二级预防为目的降脂治疗现状。同时，揭示了血脂异常二级预防在实践过程中的挑战和问题，如对未达最佳血脂标准及依从性差等问题提出了可行性方案。

>CBS CBS 2019

> CBS 2019 REGISTRATION

> CBS 2019 PROGRAM

> CBS 2019 CALL FOR SCIENCE

> CBS 2019 SPOTLIGHTS

 CBSMD

> CBSMD WEBSITE REGISTRATION

> EDUCATION CENTER

> RECOMMANDED PAPER

> TOP 10 RESEARCH PAPER

> PRE-READING

CBS 2019 CBS 2019 FACULTY Education Resource CBSMD Scientific Library
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top